LEADER 00852cam0-2200313---450- 001 990005068150403321 005 20090521143130.0 035 $a000506815 035 $aFED01000506815 035 $a(Aleph)000506815FED01 035 $a000506815 100 $a19990604d1969----km-y0itay50------ba 101 0 $aeng 102 $aGB 105 $ay-------001yy 200 1 $aAlphabets for English$fedited by W. Haas 210 $a[Manchester]$cManchester University Press$dc1969 215 $a120 p.$d22 cm 225 1 $aMont Follik series$v1 610 0 $aLingua inglese$aOrtografia 676 $a421.52 702 1$aHaas,$bWalter 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990005068150403321 952 $a421.52 HAA 1$bFil.Mod. 23854$fFLFBC 959 $aFLFBC 996 $aAlphabets for English$9531562 997 $aUNINA LEADER 04784nam 2200625Ia 450 001 9910452179203321 005 20200520144314.0 010 $a1-60876-726-4 035 $a(CKB)2550000001041251 035 $a(EBL)3018284 035 $a(SSID)ssj0000852872 035 $a(PQKBManifestationID)12365025 035 $a(PQKBTitleCode)TC0000852872 035 $a(PQKBWorkID)10864464 035 $a(PQKB)11206701 035 $a(MiAaPQ)EBC3018284 035 $a(Au-PeEL)EBL3018284 035 $a(CaPaEBR)ebr10660145 035 $a(OCoLC)923657824 035 $a(EXLCZ)992550000001041251 100 $a20090330d2009 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aMolecular therapy of breast cancer$b[electronic resource] $eclassicism meets modernity /$fMarc Lacroix 210 $aNew York $cNova Biomedical Books$dc2009 215 $a1 online resource (303 p.) 225 1 $aCancer etiology, diagnosis and treatments series 300 $aDescription based upon print version of record. 311 $a1-60741-593-3 320 $aIncludes bibliographical references and index. 327 $a""Molecular Therapy of Breast Cancer: Classicism Meets Modernity""; ""Dedication""; ""Contents ""; ""Preface""; ""Introduction ""; ""References ""; ""Selective Estrogen Receptor Modulators (SERMs) and Down-Regulators (SERDs)""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Selective Estrogen Receptor Modifiers (SERMs) ""; ""Tamoxifen ""; ""Toremifene ""; ""Fulvestrant ""; ""Conclusion ""; ""References ""; ""Aromatase Inhibitors ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Anastrozole ""; ""Letrozole ""; ""Exemestane "" 327 $a""Conclusion """"References ""; ""Agents Inducing Ovarian Suppression ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Goserelin ""; ""Triptorelin""; ""Leuprolide ""; ""Conclusion ""; ""References ""; ""Antimetabolites ""; ""Abstract ""; ""Introduction""; ""Clinical Trials in January 2009 ""; ""Fluorouracil ""; ""Capecitabine ""; ""Gemcitabine ""; ""Pemetrexed ""; ""Methotrexate ""; ""Conclusion ""; ""References""; ""Alkylating Agents ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Cyclophosphamide "" 327 $a""Platinum Compounds (Cisplatin, Carboplatin, Oxaliplatin, Picoplatin) - Generalities """"Cisplatin ""; ""Carboplatin ""; ""Oxaliplatin ""; ""Picoplatin ""; ""Temozolomide ""; ""Thiotepa""; ""Ifosfamide ""; ""Melphalan ""; ""Busulfan ""; ""Conclusion ""; ""References ""; ""Anthracyclines ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Doxorubicin ""; ""Liposomal Doxorubicin ""; ""Epirubicin ""; ""Conclusion ""; ""References""; ""Microtubule-Binding Agents ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Taxanes - Generalities "" 327 $a""Larotaxel """"Docetaxel ""; ""Paclitaxel and Nab-Paclitaxel ""; ""Epothilones - Generalities ""; ""Ixabepilone ""; ""Patupilone ""; ""Sagopilone ""; ""Vinca Alkaloids - Generalities ""; ""Vinorelbine""; ""Vinflunine ""; ""Eribulin ""; ""Conclusion ""; ""References ""; ""Topoisomerase Inhibitors ""; ""Abstract ""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Irinotecan ""; ""Etoposide ""; ""Conclusion ""; ""References""; ""HER Family Inhibitors ""; ""Abstract""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Trastuzumab ""; ""Lapatinib ""; ""Gefitinib "" 327 $a""Erlotinib """"Pertuzumab ""; ""Cetuximab ""; ""Ertumaxomab ""; ""Neratinib ""; ""Trastuzumab-MCC-DM1 ""; ""BIBW 2992 ""; ""ARRY-334543 ""; ""Conclusion ""; ""References ""; ""Angiogenesis Inhibitors ""; ""Abstract""; ""Introduction ""; ""Clinical Trials in January 2009 ""; ""Bevacizumab""; ""Sunitinib ""; ""Vandetanib ""; ""Pazopanib ""; ""Ramucirumab ""; ""ABT-869 ""; ""AV-951 ""; ""PTC299""; ""AMG 386 ""; ""Aflibercept ""; ""Conclusion""; ""References ""; ""Insulin-Like Growth Factor-I Receptor (IGF-1R) Inhibitors""; ""Abstract""; ""Introduction ""; ""Clinical Trials in January 2009"" 327 $a""Cixutumumab"" 410 0$aCancer etiology, diagnosis, and treatments. 606 $aBreast$xCancer$xMolecular aspects 606 $aAntineoplastic agents 608 $aElectronic books. 615 0$aBreast$xCancer$xMolecular aspects. 615 0$aAntineoplastic agents. 676 $a362.196/99449 676 $a362.196/99449 700 $aLacroix$b Marc$f1963-$0908647 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910452179203321 996 $aMolecular therapy of breast cancer$92084661 997 $aUNINA